Compare Intel Corp (INTC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Sana Biotechnology Inc — how do they compare? Intel Corp trades at $100.92 (market cap $492.85B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Intel Corp is far larger — about 436.2× Sana Biotechnology Inc's market cap, and Intel Corp pays a 2.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| INTC | SANA | |
|---|---|---|
Market Cap | $492.85B | $1.13B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $5.92 |
52-Week Low | $21.81 | $2.68 |
Enterprise Value | $513.66B | $1.05B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $102.74, up 5.35% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats in Q1 and Q2 2026 highlight improving operational performance, though net income remains negative. The company is raising $20 billion via a stock offering to fund AI and foundry expansion, driving investor focus on growth prospects amid margin challenges.
Outlook: Intel's revenue growth and strategic investments in AI present upside potential, but shareholder dilution from the equity raise and persistent negative margins pose risks. Analyst consensus is mixed with a $116.67 price target, suggesting cautious optimism for the turnaround story.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
